Sökning: "Johan Pontén"

Hittade 3 avhandlingar innehållade orden Johan Pontén.

  1. 1. Dissertatio botanica de Hydrocotyle, quam venia exp. Facult. Med. Upsal. præside Carol. Pet. Thunberg, ... proponit Johannes Petr. Pontén, Smolandus. in audit. botan. d. XXIV. Novemb. MDCCXCVIII

    Författare :Carl Peter Thunberg; Johan Pontén; Carl Peter Thunberg; Uppsala universitet; []
    Nyckelord :;

    Sammanfattning : .... LÄS MER

  3. 2. Spatial immune analyses in clinical cancer tissue

    Författare :Max Backman; Patrick Micke; Fredrik Pontén; Johan Botling; Kurt Schalper; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; immune landscape; non-small cell lung cancer; immune cells; multiplex immunofluorescence; spatial analysis; Medicinsk vetenskap; Medical Science;

    Sammanfattning : Cancer is a leading cause of premature death and lung cancer is the deadliest cancer type, with non-small cell lung cancer (NSCLC) representing 85% of lung cancer cases. Despite promising development in cancer treatment in recent decades, overall prognosis is poor. LÄS MER

  4. 3. An integrative strategy for targeted evaluation of biomarker expression in non-small cell lung cancer

    Författare :Johanna Mattsson; Patrick Micke; Johan Botling; Fredrik Pontén; Åslaug Helland; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; non-small cell lung cancer; prognostic biomarkers; predictive biomarkers; immunohistochemistry; gene expression; COX-2; claudin; ALK; Medicinsk vetenskap; Medical Science;

    Sammanfattning : Despite improvements in therapy, the prognosis for non-small cell lung cancer (NSCLC) patients remains poor, and cure is only possible in localized tumors after surgical resection. A new generation of targeted cancer drugs has led to the expectation that lung cancer therapy can be significantly improved, but these drugs are today only an option in a small subset of NSCLC patients, and their effect is temporary. LÄS MER